Better Insights
Empower Better Care.
Neosoma maps, measures, tracks, and consolidates longitudinal lesion data through a powerful cloud software platform purpose-built for the multidisciplinary neuro-oncology team.
Lesion Analysis Capabilities
Neosoma automates and simplifies critical tasks in lesion assessment and contouring.
Map
Neosoma maps intratumoral lesion compartments at the voxel level with accuracy, precision, and consistency.
Contour
Convert lesion maps to GTV contours and load into your TPS or neuro-nav software to support treatment planning.
Quantify
Neosoma automatically quantifies total tumor burden, tumor compartment volumes, and lesion counts, at every timepoint.
Track
Lesions are automatically tracked and categorized across all patient timepoints.
Rename and flag lesions for monitoring.
Tumor Types
Neosoma's platform is currently FDA cleared for the following tumor types:
Solution Benefits
Neosoma's platform drives significant clinical and economic benefits for
physicians, treating teams, hospitals, and patients.
Workflow Efficiencies
Automated longitudinal lesion measurement and contouring saves significant time for all specialists:
-
Auto-calculated volumetric measurements at the lesion and total tumor burden levels, at every timepoint, retrospective, current and prospective
-
Neurosurgeons and Radiation Oncologists get auto-generated GTV contours to import into their TPS software to expedite planning
Decision Support
MRI timepoints can be processed right after acquisition at the modality, providing key insights to clinicians prior to seeing patients.
The multidisciplinary team gets the benefit of an interactive web application where all data is centralized to facilitate tumor board discussions and decisioning.
Clinical Insights
Missed lesions impact patient care; Neosoma's software has been described by clinicians as "a second set of eyes," helping support their expert judgement and experience in evaluating clinical cases.
Reimbursable
Two Category 3 CPT Codes are applicable for providers to pursue reimbursement on a per-MRI-analysis basis.
Please visit our Reimbursement page for more details.
In Clinicians' Own Words
“Clinicians commonly debate the results of brain MRIs and whether the brain tumor is stable, responding to treatment, or progressing. Neosoma HGG will give us the objectivity needed to make our decisions easier and more accurate.”
Isabelle M. Germano, MD, MBA, FACS
Professor of Neurosurgery and Director of the Comprehensive Brain Tumor Program at the Icahn School of Medicine at Mount Sinai
In Collaboration with Leading Clinical Sites
Latest Research and Publications
Artificial intelligence-based volumetric measurements for longitudinal clinical assessment of treatment response in high-grade gliomas: Validation across institutional and public datasets
Contrast-enhancing (CE) tumor volumes were consistent across AI platforms, and Neosoma HGG significantly reduced segmentation time (pre-operative: 210.5s, post-operative: 179s vs. 15 s, P < .0001). AI-informed disease state assessments showed an overall moderate agreement with MDTB diagnoses for progressive disease (k = 0.45, P < .00001). Key discrepancies arose from limitation of Neosoma HGG in distinguishing pseudo-progression from tumor progression.
Evaluation of compartmentalized automatic segmentation for definition of the GTV in glioblastoma radiotherapy
Inselspital and UBern studied Neosoma Glioma's auto-contours, comparing time savings and contour accuracy vs. expert manual contours, concluding that the Neosoma Glioma model generates clinically useful postoperative GTV segmentations, with geometric performance comparable to expert variability and dosimetric equivalence to consensus contours, and reducing contouring time by over 50%, enabling faster RT workflows.
